IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

RUTH SMITH, Individually and as Widow for the)
Use and Benefit of Herself and the Next Kin of)
Richard Smith, Deceased,)
Plaintiff,) Oivil No. 3:05-0444 Judge Aleta A. Trauger
v.) (Dist. Of MA No.) 1:05-cv-11515PBS)
PFIZER, INC., et al.,)
Defendants.)

DEFENDANTS' MOTION IN LIMINE TO EXCLUDE EVIDENCE OF POST-INCIDENT REGULATORY ACTIONS, LABELING, AND PATIENT INFORMATION GUIDES

Pursuant to Federal Rules of Evidence 401, 402, 403, and 407, Defendants Pfizer Inc and Warner-Lambert Company LLC (collectively, "Defendants" or "Pfizer") respectfully move this Court for an order *in limine* to exclude at trial all evidence of and references to Food and Drug Administration ("FDA") regulatory actions related to Neurontin, including labeling, labeling changes, and patient information guides for Neurontin, that were issued after Mr. Smith's death in May 2004. This evidence has no bearing on the adequacy of Neurontin's warnings at the time it was prescribed to and allegedly taken by Mr. Smith, and is therefore irrelevant under Rules 401 and 402. Moreover, the likelihood that this evidence would unfairly prejudice Pfizer and mislead and confuse the jury substantially outweighs its probative value, if any, requiring its exclusion under Rule 403. Finally, this evidence is a subsequent remedial measure under Rule 407 and is therefore inadmissible to demonstrate liability. Accordingly, all such evidence must be excluded.

The grounds for this motion are set forth in more detail in the accompanying memorandum of law and Declaration of Mark S. Cheffo.

WHEREFORE, Defendants respectfully request that the Court exclude at trial all evidence of and references to FDA regulatory actions related to Neurontin, including labeling,

labeling changes, and patient information guides for Neurontin, that were issued after Mr. Smith's death in May 2004.

Dated: April 16, 2010

Respectfully submitted,

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

By: /s/ Mark S. Cheffo Mark S. Cheffo

Four Times Square New York, NY 10036 Tel: (212) 735-3000

-and-

NEAL & HARWELL, PLC

By: /s/ Gerald D. Neenan
Aubrey B. Harwell, Jr., No. 002559
W. David Bridgers, No. 016603
Gerald D. Neenan, No. 006710

2000 One Nashville Place 150 Fourth Avenue, North Nashville, TN 37219 (615) 244-1713 (615) 726-0573 (fax)

Attorneys for Defendants Pfizer Inc and Warner-Lambert Company LLC

CERTIFICATE OF SERVICE

I hereby certify that on this the 16th day of April 2010, I electronically filed the foregoing document with the Clerk of the Court, United States District Court for the Middle District of Tennessee, using the CM/ECF system. True and correct copies of the foregoing documents are being served via the Court's CM/ECF system on the following:

Andrew G. Finkelstein, Esq. Kenneth B. Fromson, Esq. Finkelstein & Partners, LLP 436 Robinson Avenue Newburg, NY 12550

Dara G. Hegar, Esq. Ken S. Soh, Esq. Maura Kolb, Esq. Robert Leone, Esq. W. Mark Lanier, Esq.

Lanier Law Firm 6810 FM 1960 West Houston, TX 77069 Charles F. Barrett, Esq. Barrett & Associates, P.A. 6718 Highway 100, Suite 210 Nashville, TN 37205

/s/ Gerald D. Neenan